Developing of polymeric micelle for molecular targeting to cancer stem cells in ovarian cancer patients.

开发用于分子靶向卵巢癌患者癌症干细胞的聚合物胶束。

• 批准号: 22659303
• 负责人: OHMICHI Masahide
• 金额: $ 2.11万
• 依托单位: Osaka Medical College
• 依托单位国家: 日本
• 项目类别: Grant-in-Aid for Challenging Exploratory Research
• 财政年份: 2010
• 资助国家: 日本
• 起止时间: 2010 至 2012
• 项目状态: 已结题
• 来源: https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-22659303/
• 关键词: CD24, 婦人科悪性腫瘍; 上皮間葉形質転換; EMT, 高分子ミセル; 抗癌剤耐性; CD24; 婦人科悪性腫瘍; EMT; 高分子ミセル; 癌幹細胞; 卵巣癌; GPR30; ミセル; 白金製剤耐性卵巣癌; EGFR

The epithelial-mesenchymal-transition (EMT) is an important step in the invasion and metastasis of cancer cells. EMT is an important step in the invasion and metastasis of cancer. G protein-coupled receptor 30 (GPR30) is a 7-transmembrane estrogen receptor that functions alongside traditional estrogen receptors to regulate the cellular responses to estrogen. Current study suggested that the expression of both GPR30 and EGFR is associated with a poor outcome in ovarian cancer, and GPR30 increases the phosphorylation of Akt via the EGFR in ovarian cancer cells. The regulation of GPR30 might be a potentially useful new therapeutic target in ovarian cancer. Furthermore, Recently CD24 has been considered as a prognostic maker in various cancers. So we analyzed the prognostic impact of the CD24 expression in ovarian cancer by immunostaining. The CD24 expression was significantly associated with FIGO stage, lymph node metastasis and peritoneal metastasis. The in vitro examination showedthat high expression level of CD24 is significantly associated with EMT positivity. In addition, the CD24 overexpression increased invasiveness, and knockdown of CD24 suppressed cell invasion. In conclusion CD24 expression in ovarian cancer may be related to tumor invasion and migration. Based on the results, the anti-cancer agent incorporated polymeric micelles, which have anti-GPR30 or anti-CD24 antibodies in their outer layer, are in development

上皮 - 间质转换（EMT）是癌细胞侵袭和转移的重要一步。 EMT是癌症侵袭和转移的重要一步。 G蛋白偶联受体30（GPR30）是一种7跨膜雌激素受体，与传统的雌激素受体一起起作用，以调节细胞对雌激素的反应。当前的研究表明，GPR30和EGFR的表达与卵巢癌的结果差有关，而GPR30在卵巢癌细胞中通过EGFR增加了AKT的磷酸化。 GPR30的调节可能是卵巢癌的潜在有用的新治疗靶标。此外，最近CD24被认为是各种癌症的预后制造商。因此，我们通过免疫染色分析了CD24表达在卵巢癌中的预后影响。 CD24表达与FIGO期，淋巴结转移和腹膜转移显着相关。体外检查表明CD24的高表达水平与EMT阳性显着相关。此外，CD24的过表达增加了侵袭性，CD24抑制了细胞侵袭。总之，CD24在卵巢癌中的表达可能与肿瘤侵袭和迁移有关。根据结果​​，抗癌剂掺入了外层具有抗GPR30或抗CD24抗体的聚合物胶束，正在发育中

项目成果

卵巣癌の播種転移はEMT現象を反映する

卵巢癌播散转移反映EMT现象

• 发表时间: 2012
• 作者: Osawa Y;Suzuki D;et al.;Kiyoko Kato;高井雅聡
• 通讯作者: 高井雅聡

白金製剤耐性卵巣癌におけるAktをターゲットとした分子標的薬としてのGemcitabineの機能解析

吉西他滨作为 Akt 分子靶向药物在铂耐药卵巢癌中的功能分析

• 发表时间: 2012
• 作者: Nakashima A;Shima T;Inada K;Ito M;Saito S;川口浩史
• 通讯作者: 川口浩史

Prognostic impact of EMT (epithelial-mesenchymal-transition)-related protein expression in endometrial cancer.

• DOI: 10.4161/cbt.22625
• 发表时间: 2013-01
• 期刊: Cancer biology & therapy
• 影响因子: 3.6
• 作者: Tanaka Y;Terai Y;Kawaguchi H;Fujiwara S;Yoo S;Tsunetoh S;Takai M;Kanemura M;Tanabe A;Ohmichi M
• 通讯作者: Ohmichi M

卵巣癌における EGFR 遺伝子変異とその下流 シグナル分子の発現解析

卵巢癌中EGFR基因突变及其下游信号分子的表达分析

• 发表时间: 2010
• 作者: Oishi N;Inoue Y;Ogawa K他3名;加藤聖子;田中良道
• 通讯作者: 田中良道

卵巣癌治療の新たな展開

卵巢癌治疗新进展

• 发表时间: 2011
• 作者: Hasegawa T.;Yonezawa R.;Shima T.;Tatematsu M.;Nakashima A.;Hidaka T.;Saito S.;大道正英
• 通讯作者: 大道正英